Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 30, 2005

View Archived Issues

Orexo and ProStrakan sign European licensing agreement for Rapinyl

Targacept and AstraZeneca sign license and research collaboration agreement

AstraZeneca to acquire KuDOS Pharmaceuticals

Kissei and JCR sign joint research agreement for JR-013

Mixed results from phase I/II study of CER-227185 in AML

Exelixis signs agreement for taxane production from plant cell culture

Therion secures funding to advance clinical development program

New HIV integrase inhibitors claimed in recent Bristol-Myers Squibb patent

Novel antiinfective agents disclosed in recent patent literature

TRPV5: An essential Ca2+ transporter in osteoclastic bone resorption

Novel antibiotic effective against Clostridium difficile-associated diarrhea

Bexel Pharmaceuticals presents results on a novel antiobesity compound

ABT-737, a potential drug for cancer therapy

Approvable letter for Vivitrol

Femara receives new U.S. approval

Further development of Tanox's novel HIV drug TNX-355 supported by recent data

New anti-proinflammatory cytokine pharmacotherapeutics for the treatment of inflammatory arthritis

Study provides new insights into the antiosteoarthritic properties of rhein

Cathepsin K inhibition for the treatment of osteoarthritis

Recent AstraZeneca patents report novel cannabinoid CB1 receptor modulators

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...